Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Short Interest Up 24.7% in February

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) saw a significant increase in short interest in February. As of February 13th, there was short interest totaling 20,891 shares, an increase of 24.7% from the January 29th total of 16,753 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average trading volume of 63,537 shares, the days-to-cover ratio is currently 0.3 days. Based on an average trading volume of 63,537 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.4% of the shares of the company are short sold.

Chemomab Therapeutics Stock Performance

Shares of NASDAQ:CMMB traded up $0.08 during midday trading on Wednesday, reaching $1.87. 8,756 shares of the company’s stock traded hands, compared to its average volume of 86,968. The company has a fifty day simple moving average of $1.67 and a two-hundred day simple moving average of $2.43. Chemomab Therapeutics has a 1 year low of $1.35 and a 1 year high of $6.14. The company has a market cap of $11.52 million, a P/E ratio of -0.63 and a beta of 0.41.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CMMB shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Chemomab Therapeutics in a research note on Monday, December 29th. Zacks Research downgraded shares of Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $25.00.

Institutional Trading of Chemomab Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new position in shares of Chemomab Therapeutics during the 4th quarter worth about $31,000. Kestra Private Wealth Services LLC purchased a new position in shares of Chemomab Therapeutics in the fourth quarter valued at approximately $85,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Chemomab Therapeutics in the fourth quarter worth approximately $132,000. Hedge funds and other institutional investors own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.